Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dalpiciclib plus camrelizumab for CDK4-amplified recurrent/metastatic head and neck mucosal melanoma
ChiCTR2300073726Phase 2Not yet recruiting
- Sponsor
- Shanghai Ninth People's Hospital
- Start
- Jul 2023
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of dalpiciclib and camrelizumab in mucosal melanoma (MM), sponsored by Shanghai Ninth People's Hospital. Primary endpoint: Progression-free survival. Planned start Jul 2023; status: not yet recruiting.
02
Drugs
dalpiciclibcamrelizumab
03
Conditions
mucosal melanoma (MM)
Beyond the preview
Go deeper on ChiCTR2300073726.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300073726.